Plakoula E, Kalampounias G, Alexis S, Verigou E, Kourakli A, Zafeiropoulou K
Curr Issues Mol Biol. 2025; 47(1).
PMID: 39852147
PMC: 11763810.
DOI: 10.3390/cimb47010032.
Upadhyay A, Joshi V
ACS Pharmacol Transl Sci. 2024; 7(9):2573-2587.
PMID: 39296276
PMC: 11406696.
DOI: 10.1021/acsptsci.4c00278.
Federici L, Masulli M, De Laurenzi V, Allocati N
Nutrients. 2024; 16(16).
PMID: 39203889
PMC: 11357436.
DOI: 10.3390/nu16162753.
Liu L, Lucero B, Manriquez-Rodriguez C, Francisco K, Teixeira T, Yohannan D
ACS Omega. 2024; 9(32):34829-34840.
PMID: 39157084
PMC: 11325529.
DOI: 10.1021/acsomega.4c04316.
Vignard V, Baruteau A, Toutain B, Mercier S, Isidor B, Redon R
Front Cell Dev Biol. 2024; 12:1370905.
PMID: 39071803
PMC: 11272537.
DOI: 10.3389/fcell.2024.1370905.
Targeted Therapies in the Treatment of Mantle Cell Lymphoma.
Thomas C, Carvajal V, Barta S
Cancers (Basel). 2024; 16(10).
PMID: 38792015
PMC: 11119355.
DOI: 10.3390/cancers16101937.
The role of proteasomes in tumorigenesis.
Zhou X, Xu R, Wu Y, Zhou L, Xiang T
Genes Dis. 2024; 11(4):101070.
PMID: 38523673
PMC: 10958230.
DOI: 10.1016/j.gendis.2023.06.037.
Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence.
Chua A, Thaarun T, Yang H, Lee A
Health Sci Rep. 2023; 6(11):e1443.
PMID: 38028684
PMC: 10643516.
DOI: 10.1002/hsr2.1443.
Induction of proteasomal activity in mammalian cells by lifespan-extending tRNA synthetase inhibitors.
Mariner B, Rodriguez A, Heath O, McCormick M
Geroscience. 2023; 46(2):1755-1773.
PMID: 37749371
PMC: 10828360.
DOI: 10.1007/s11357-023-00938-8.
RNF4 and USP7 cooperate in ubiquitin-regulated steps of DNA replication.
Chang Y, Lin K, Baxley R, Durrett W, Wang L, Stojkova O
Open Biol. 2023; 13(8):230068.
PMID: 37607592
PMC: 10444366.
DOI: 10.1098/rsob.230068.
Organoboronic acids/esters as effective drug and prodrug candidates in cancer treatments: challenge and hope.
Al-Omari M, Elaarag M, Al-Zoubi R, Al-Qudimat A, Zarour A, Al-Hurani E
J Enzyme Inhib Med Chem. 2023; 38(1):2220084.
PMID: 37318308
PMC: 10351539.
DOI: 10.1080/14756366.2023.2220084.
Sequential Ubiquitination and Phosphorylation Epigenetics Reshaping by MG132-Loaded Fe-MOF Disarms Treatment Resistance to Repulse Metastatic Colorectal Cancer.
Bu Z, Yang J, Zhang Y, Luo T, Fang C, Liang X
Adv Sci (Weinh). 2023; 10(23):e2301638.
PMID: 37303273
PMC: 10427397.
DOI: 10.1002/advs.202301638.
Molecular Mechanisms Driving and Regulating the AAA+ ATPase VCP/p97, an Important Therapeutic Target for Treating Cancer, Neurological and Infectious Diseases.
Valimehr S, Sethi A, Shukla M, Bhattacharyya S, Kazemi M, Rouiller I
Biomolecules. 2023; 13(5).
PMID: 37238606
PMC: 10216129.
DOI: 10.3390/biom13050737.
Complexity in radiological morphology predicts worse prognosis and is associated with an increase in proteasome component levels in clear cell renal cell carcinoma.
Kobatake K, Ikeda K, Teishima J, Sekino Y, Babasaki T, Kohada Y
Front Oncol. 2022; 12:1039383.
PMID: 36568232
PMC: 9773190.
DOI: 10.3389/fonc.2022.1039383.
Polystyrene nanoplastics affect the human ubiquitin structure and ubiquitination in cells: a high-resolution study.
Della Valle M, DAbrosca G, Gentile M, Russo L, Isernia C, Di Gaetano S
Chem Sci. 2022; 13(45):13563-13573.
PMID: 36507175
PMC: 9682910.
DOI: 10.1039/d2sc04434j.
MLN2238 exerts its anti-tumor effects regulating ROS/JNK/mitochondrial signaling pathways in intrahepatic cholangiocarcinoma.
Xu H, Xu G, Xu Q, Xu C, Zhou X, Bai Y
Front Pharmacol. 2022; 13:1040847.
PMID: 36386204
PMC: 9659592.
DOI: 10.3389/fphar.2022.1040847.
Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H, Endo J, Kitakata H, Moriyama H, Sano M, Fukuda K
Int J Mol Sci. 2022; 23(11).
PMID: 35683015
PMC: 9181426.
DOI: 10.3390/ijms23116336.
The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
Op M, Ribeiro S, Chavarria C, de Gassart A, Zaffalon L, Martinon F
Cell Death Dis. 2022; 13(5):475.
PMID: 35589686
PMC: 9120136.
DOI: 10.1038/s41419-022-04925-3.
Overcoming drug resistance by targeting protein homeostasis in multiple myeloma.
Moscvin M, Ho M, Bianchi G
Cancer Drug Resist. 2022; 4:1028-1046.
PMID: 35265794
PMC: 8903187.
DOI: 10.20517/cdr.2021.93.
Site-Specific Proteasome Inhibitors.
Kisselev A
Biomolecules. 2022; 12(1).
PMID: 35053202
PMC: 8773591.
DOI: 10.3390/biom12010054.